

**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Carl J. Pepine, M.D.		POSITION TITLE	
eRA COMMONS USER NAME		Professor of Medicine	
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of Pittsburgh, Pittsburgh, PA New Jersey Medical School, Newark, NJ	B.S. M.D.	1959-62 1962-66	Premedical Medicine

**A. Positions and Employment**

1966-67 Intern, Dept of Med, Allegheny Gen Hospital, Pittsburgh, PA  
 1967-71 Medical Resident and Fellow in Cardiology, Jefferson Medical College Hospital and Regional Naval Medical Center, Philadelphia, PA  
 1971-74 Instructor (71-72), Assistant Prof of Medicine (72-74), Jefferson Medical College, Philadelphia, PA  
 1971-74 Director, Cardiac Catheterization Laboratory, and LCDR, USN(MC) Medical Research Laboratory, Naval Regional Medical Center, Philadelphia, PA  
 1974 Asst. Prof. (74-75), Assoc. Prof. (75-79), Prof. of Medicine (79- ), Division of Cardiovascular Medicine, University of Florida (UF), College of Medicine, Gainesville, FL  
 1974-86 Medical Director, Cardiac Catheterization Lab, Shands Hospital UF and VAMC, Gainesville, FL  
 1978-94 Chief, Cardiology, VA Medical Center, Gainesville, FL  
 1979-84 Principal Investigator, NHLBI-PTCA Registry  
 1979 Professor, School of Graduate Studies, UF, Gainesville, FL  
 1982-98 Co-Director, Division of Cardiovascular Medicine, Department of Medicine, UF  
 1985-92 Principal Investigator, NHLBI-Studies of LV Dysfunction (SOLVD)  
 1989-93 Co-PI, NHLBI-Thrombolysis in Myocardial Infarction III-A (TIMI III-A)  
 1990-93 Co-PI, NHLBI-Balloon Valvuloplasty Registry  
 1990-94 Principal Investigator, NHLBI-Asymptomatic Cardiac Ischemia (ACIP)  
 1991-96 Principal Investigator, NHLBI-Psychophysiologic Interventions in Myocardial Ischemia (PIMI)  
 1996- Principal Investigator, NHLBI-Women's Ischemia Syndrome Evaluation (WISE)  
 1998- Chief, Division of Cardiovascular Medicine, Department of Medicine, UF  
 2001- Eminent Scholar, American Heart Association – Suncoast Chapter Chair, Inc.

**Honors (selected):** Distinguished International Educator, UF (2005); Gifted Teacher Award, FL Chp Am Coll of Cardiol (2001); Research Foundation Professorship Award, UF (1999-2001); Master, Am Coll of Cardiol (1999); Theodore E. Woodward Award, Am CL and Climatological Assoc (1998); Professorial Excellence Program (PEP) Award, UF Health Science Center (1996-97); Paul Dudley White Award, AMSUS (1991); Res Achievement Award, UF (1990,91,92,93); Pioneer Investigator Award, Int'l Soc Holter Monitoring (1990); Clinical Faculty Prize in Res, UF Coll of Med (1989); Alpha Omega Alpha

**Committees (selected):** Chair DSMB NHLBI-FREEDOM Clinical Trial (2004-); ACC President (2003-04); Session Moderator NHLBI workshop on Women and Ischemia Syndrome (10/02); Co-Chair NHLBI workshop on Psycho-social Influences on CV Disease: Future Research Directions (9/02); ACC Vice-President (2001-2002); ACC BOT (1986-88, 1990-95, 2001-present); NHLBI Clinical Trials Review Committee Chair (2001-2003), member (1999-2003); ACC/AHA Task Force for Unstable Angina (1998-2000, 2002); ACC/AHA Task Force for Coronary Angiography (1985-87, 95-2000); Subcommittee Training Standards in Interventional Cardiology (1997-2000); Chairman Subcommittee ACC Self Assessment Program (CathSAP) in Cardiac Catheterization (1996-2000); Chairman ACC Expert Consensus Document on Coronary Artery Stents (1995-1996); Chairman ACC Cardiac Catheterization Committee (1990-96)

**B. Selected peer-reviewed publications** (selected from over 600)

1. **Pepine CJ**. Rationale for calcium antagonists in patients with hypertension complicated by ischaemic heart disease. *Int J Clin Prac Symposium Suppl* 1:31S-38S, 1987.
2. Nichols WW, Nicolini FA, **Pepine CJ**. Determinants of isolated systolic hypertension in the elderly. *J Hypertens* 10:S73-S77, 1992.
3. **Pepine CJ**. Systemic hypertension and coronary artery disease. *Am J Cardiol* 82:21H-24H, 1998.
4. **Pepine CJ**, Handberg-Thurmond E, Marks RG, Conlon M, Cooper-DeHoff R, Volkers P, Zellis P for the INVEST Investigators. Rationale and design of the INternational VErapamil SR/trandolapril STudy (INVEST): An Internet-based randomized trial in coronary artery disease patients with hypertension. *J Am Coll Cardiol* 32:1228-37, 1998.
5. **Pepine CJ**. Guest Editor: The INternational VErapamil SR/trandolapril STudy (INVEST) – The first randomized clinical trial evaluating aggressive blood pressure management (JNC VI) in patients with CAD. *Clin Cardiol* 24:V1-V30, 2001.
6. **Pepine CJ**, Handberg EM. The vascular biology of hypertension and atherosclerosis and intervention with calcium antagonists and angiotensin-converting enzyme inhibitors. *Clin Cardiol* 24:V1-V5, 2001.
7. **Pepine CJ**, Cooper-DeHoff RM, Weiss RJ, Koren M, Bittar N, Thadani U, Minkwitz MC, Michelson EL, Hutchinson HG. Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris. *Am J Cardiol* 91:274-79, 2003.
8. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancina G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW, for the INVEST investigators. A Calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. *JAMA* 290:2805-16, 2003.
9. **Pepine CJ**, Conti CR. Managing hypertension in European patients with coronary artery disease: Design, results, and clinical implications of INVEST. *Ital Heart J* 5:411-16, 2004.
10. **Pepine CJ**, Cooper-DeHoff RM. Cardiovascular therapies and risk for development of diabetes. *J Am Coll Cardiol* 44:509-12, 2004.
11. Bakris GL, Gaxiola E, Messerli FH, Mancina G, Erdine S, Cooper-DeHoff R, **Pepine CJ**, for the INVEST Investigators. Clinical outcomes in the diabetes cohort of the International Verapamil SR-Trandolapril Study. *Hypertension* 44:637-42, 2004.
12. Cooper-DeHoff RM, Handberg EM, Cohen J, Kowey P, Messerli FH, Mancina G, Cangiano JO, Gaxiola E, Garcia-Barreto D, Hewkin AC, **Pepine CJ**, for the INVEST Investigators. Characterisitcis of contemporary patients with hypertension and coronary artery disease. *Clin Cardiol* 27:571-6, 2004.
13. **Pepine CJ**. Editorial: What is the optimal blood pressure and drug therapy for patients with coronary artery disease? *JAMA* 292:2271-73, 2004.
14. Messerli FH, Kupfer S, **Pepine CJ**. J curve in hypertension and coronary artery disease. *Am J Cardiol* 95:160, 2005.
15. Ried LD, Tueth MJ, Handberg E, Kupfer S, **Pepine CJ**, and the INVEST Study Group. A study of antihypertensive durgs and depressive symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension treatment strategy in the INternational VErapamil SR-trandolapirl STudy (INVEST). *Psychosom Med* 67:398-406, 2005.
16. Zineh I, Cooper-DeHoff RM, Wessel TR, Arant CB, Sleight P, Geiser EA, **Pepine CJ**. Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-trandolapril STudy (INVEST). *Clin Cardiol* 28(7):321-328, 2005.
17. Nathan S, **Pepine CJ**, Bakris GL. Calcium antagonists: Effects on cardio-renal risk in hypertensive patients. *Hypertension* 46:637-42, 2005.
18. Elliott WJ, Hewkin AC, Kupfer S, Cooper-DeHoff R, **Pepine CJ**. A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients. *J Clin Hypertens* 7:654-63, 2005.
19. **Pepine CJ**, Kowey PR, Kupfer S, Kollock RE, Benetos A, Mancina G, Coca A, Cooper-DeHoff RM, Handberg E, Gaxiola E, Sleight P, Conti CR, Hewkin AC, Tavazzi L, for the INVEST Investigators. Predictors of adverse outcome among patients with hypertension and coronary artery disease. *J Am Coll Cardiol* 47:547-51, 2006.
20. Gierach GL, Johnson BD, Bairey Merz CN, Kelsey SF, Bittner V, Olson MB, Shaw LJ, Mankad S, **Pepine CJ**, Reis SE, Rogers WJ, Sharaf BL, Sopko G, for the WISE Study Group. Hypertension, menopause, and coronary artery disease risk in the Women's Ischemia Syndrome Evaluation (WISE) study. *J Am Coll Cardiol* 47(3):50S-58S, 2006
21. Ried LD, Tueth MJ, Taylor MD, Sauer BC, Lopez LM, **Pepine CJ**. Depressive symptoms in coronary artery disease patients after hypertension treatment. *Ann Pharmacother* 40:##, 2006.

22. Cooper-DeHoff R, Cohen JD, Bakris GL, Messerli FH, Erdine S, Hewkin AC, Kupfer S, **Pepine CJ**, for the INVEST Investigators. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications: Findings from the INternational VERapamil SR-trandolapril STudy (INVEST). *Am J Cardiol* 2006;in press (ms#AJC-D-06-00435)
23. Cooper-DeHoff RM, Aranda JM, Gaxiola E, Cangiano JL, Garcia-Barreto D, Conti CR, Hewkin A, **Pepine CJ**. Blood pressure control and cardiovascular outcomes in high risk Hispanic patients – Findings from the International Verapamil SR – Trandolapril Study. *Am Heart J* 2006;in press (ms#AHJ 1394)
24. Messerli FH, Mancia G, Conti CR, Hewkin A, Kupfer S, Champion A, Kolloch R, Benetos A, **Pepine CJ**. Dogma disputed: The J-curve in hypertensive patients with coronary artery disease: The INternational VERapamil-trandolapril STudy (INVEST). *Ann Intern Med* 2006;in press.

### C. Research Support

#### Active

2153101

12/01 – present

AHA

*Eminent Scholar Chair – AHA Suncoast*

To promote the mission of the AHA in reducing disability and death from cardiovascular disease.

HL03 001

Johnson(PI)

9/03 – 8/07

NIH/NHLBI

*Hypertension Pharmacogenetics*

To determine the role of assessing population stratification and ancestral proportions using genetic markers in pharmacogenetic studies.

Role: Co-Investigator

U01 HL64924-01 (343-2001)

Pepine(PI)

7/01 – 5/06

NIH/NHLBI

*Altered Renin Angiotensin System as a Mechanism for Coronary Microvascular Dysfunction in Women (WISE-2)*

To determine the influence of angiotensin-renin system on coronary macro and microvascular dysfunction in women with chest pain and/or cardiac ischemia in the absence of flow limiting stenoses.

Role: Principal Investigator

U01 HL64829-01

Kelsey(PI)

4/01 – 3/06

NIH/NHLBI

*Women's Ischemia Syndrome Evaluation (WISE)*

To determine incremental long-term prognostic value of novel testing developed in WISE, develop sex-specific incremental outcome models to evaluate prognostic value of female reproductive variables, assess incremental cost effectiveness and resource efficiency of WISE innovative testing techniques as compared with traditional tests, and continue ongoing analyses and ancillary projects.

Role: Principal Investigator for UF site

N01-HV-68163

Pepine(PI)

9/97 – 9/05

NIH/NHLBI

*Women's Ischemic Syndrome Evaluation (WISE-IVUS)**Substudy: Intracoronary Ultrasound Evaluation of Women with Chest Pain and Microvascular Dysfunction*

To further define characteristics of coronary disease in women with chest pain and microvascular dysfunction.

Role: Principal Investigator

536-1996

Pepine(PI)

3/97 - 12/05

Abbott Laboratories

*International VERapamil-trandolapril STudy (INVEST)*

To assess effectiveness of different treatment strategies for hypertension in patients with coronary artery disease.

Role: Principal Investigator

661-2000

Johnson(PI)

1/01 – 1/06

Abbott Laboratories

*Heart Disease Outcomes: Impact of Genetics and Pharmacogenetics*

Investigate genetic determinants of disease progression in INVEST patients and genetic contributions to variable drug response for INVEST drugs.

Role: Co-Principal Investigator

252-2002

Pepine(PI)

9/2/02 – 6/11/04

Abbott Laboratories

*INVEST Renal Substudy*

A substudy to evaluate whether an antihypertensive treatment strategy initiated with a heart rate slowing calcium antagonist (verapamil SR) in a large population of CAD pts, slows progression or development of renal dysfunction compared with an antihypertensive treatment strategy initiated with a  $\beta$ -adrenergic blocker (atenolol).

Role: Principal Investigator

Abbott Laboratories

Pepine(PI)

4/05 – 3/06

*INVEST Publication Coordinating Center*

To facilitate the publication of manuscripts from the INVEST.

Role: Principal Investigator

406-2001

Pepine(PI)

12/01 – 10/05

Berlex Laboratories, Inc.

*Angiogenetic Gene Therapy, Protocol 304386*

A study to evaluate the efficacy and safety of intracoronary Ad5.0FGF-4 in CAD patients with stable angina.

Role: Principal Investigator

482-1998

Pepine(PI)

3/00 – 12/05

Pfizer, Inc.

*A Double-Blind, Multicenter, Placebo Controlled Study of Quinapril in Women with Chest Pain, Coronary Flow Reserve Limitations and Evidence of Myocardial Ischemia in the Absence of Significant Epicardial Coronary Artery Disease (QWISE)*

An extramural funded WISE ancillary study to evaluate effects of ACE inhibition in women with chest pain.

Role: Principal Investigator

107-1998

Schmalfuss(PI)

6/98 – 6/05

Pfizer, Inc.

*The Effect of LDL-Cholesterol Lowering Beyond Currently Recommended Minimum Targets on Coronary Heart Disease (CHD) Recurrence in Patients with Preexisting CHD (TNT)*

A multicenter, randomized evaluation of lower targets for LDL cholesterol in patients with CAD.

Role: Co-Investigator

060-2002

Pepine(PI)

3/02 – 2/06

Pfizer, Inc.

*Effects of Sildenafil on Vascular Function in Women with Chest Pain*

A study to evaluate the effect of PDE-5 inhibition (sildenafil) on coronary flow reserve, brachial artery reactivity, and arterial pulse wave velocity in women with microvascular dysfunction but no CAD.

Role: Principal Investigator

219-2001

Dehoff(PI)

4/02 – 4/05

Pfizer, Inc.

*A Pilot Study to Determine the Effect of Celecoxib 400 mg and 800 mg on Markers of Inflammation in Patients with Hypertension and Coronary Artery Disease.*

Pilot study to determine the timing and dose of selective COX-2 inhibition (celecoxib) required to effect plasma markers of inflammation and brachial artery reactivity in CAD patients with hypertension.

Role: Co-Principal Investigator

### **Pending**

R01 HL084038-01

Pepine(PI)

4/06 – 3/09

NIH/NHLBI

*Prospective Investigations OF CAD (PIOCAD) Core Angiographic Laboratory (CAL)*

To determine the diagnostic accuracy of 64-slice multidetector spiral computed tomography for the minimally invasive diagnosis of CAD. Reviewed and received score of 167